Calcium Activation of the Androgen Receptor in Prostate Cells
CONCLUSIONS: The results of this study show that calcium activates AR and increases cell growth and that calcium channels are overexpressed in hormone-responsive and hormone-resistant prostate cancer cells. Taken together, the results suggest a novel role of calcium in the castration-resistant phenotype.PMID:38131032 | PMC:PMC10733593 | DOI:10.1155/2023/9907948 (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - December 22, 2023 Category: Endocrinology Authors: Zeina W Sharawi Sawsan M Khatrawi Qiaochu Wang Hongzhao Zhou Kedra Cyrus Gai Yan Becky Hoxter Bassem R Haddad Mary Beth Martin Source Type: research

Narirutin. A flavonoid found in citrus fruits modulates cell cycle phases and inhibits the proliferation of hormone-refractory prostate cancer cells by targeting hyaluronidase
Food Chem Toxicol. 2023 Jan 25:113638. doi: 10.1016/j.fct.2023.113638. Online ahead of print.ABSTRACTNarirutin is a dietary flavanone found in lemons, oranges, passion fruit, bergamot and grapefruit. It possesses anti-allergic, cardioprotective, neuroprotective, hepatoprotective potential, and its enriched fraction suppresses the growth of prostate cancer cells; however, there is currently no information on the chemopreventive potential of narirutin alone against hormone-refractory prostate cancer cells (PC-3) and its mode of action. Thus, the chemopreventive possibility of narirutin was investigated in PC-3 cells by utili...
Source: Food and Chemical Toxicology - January 28, 2023 Category: Food Science Authors: Shilpi Singh Akhilesh Kumar Maurya Abha Meena Nidhi Mishra Suaib Luqman Source Type: research

Narirutin. A flavonoid found in citrus fruits modulates cell cycle phases and inhibits the proliferation of hormone-refractory prostate cancer cells by targeting hyaluronidase
Food Chem Toxicol. 2023 Jan 25:113638. doi: 10.1016/j.fct.2023.113638. Online ahead of print.ABSTRACTNarirutin is a dietary flavanone found in lemons, oranges, passion fruit, bergamot and grapefruit. It possesses anti-allergic, cardioprotective, neuroprotective, hepatoprotective potential, and its enriched fraction suppresses the growth of prostate cancer cells; however, there is currently no information on the chemopreventive potential of narirutin alone against hormone-refractory prostate cancer cells (PC-3) and its mode of action. Thus, the chemopreventive possibility of narirutin was investigated in PC-3 cells by utili...
Source: Cell Research - January 28, 2023 Category: Cytology Authors: Shilpi Singh Akhilesh Kumar Maurya Abha Meena Nidhi Mishra Suaib Luqman Source Type: research

The Case | Hematuria, proteinuria, and renal insufficiency in metastatic prostate cancer
A 75-year-old man with metastatic hormone-resistant prostate cancer and well-controlled hypertension on amlodipine presented with lower limb swelling for 2 weeks. Two years before presentation, he had surgical resection of a destructive bony metastasis in the right innominate bone, followed by stereotactic whole-body radiation therapy and anti-androgen and gonadotropin-releasing hormone antagonists. Despite an 8-month course of prostate-specific membrane antigen (PSMA) –targeted radioligand therapy with 177Lu-PSMA (total 1154 mCi over 6 doses) that was completed 2 months before presentation, the cancer remained progressi...
Source: Kidney International - September 20, 2022 Category: Urology & Nephrology Authors: Jiashen Cai, Cynthia C. Lim, Hui Zhuan Tan, Jason C.J. Choo, Puay Hoon Tan Tags: Make Your Diagnosis Source Type: research

Emerging hormonal agents for the treatment of prostate cancer
Expert Opin Emerg Drugs. 2022 Sep 9:1-9. doi: 10.1080/14728214.2022.2121390. Online ahead of print.ABSTRACTINTRODUCTION: Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal alternatives. The landscape of prostate cancer treatment has transformed and taken shape over the last 20 years with novel hormonal and non-hormonal therapeutics that have demonstrated significant improvement in survival. However, patients with advanced disease still face imminent progression on ...
Source: Expert Opinion on Emerging Drugs - September 5, 2022 Category: Drugs & Pharmacology Authors: Emily Bochner Sam Gold Ganesh V Raj Source Type: research

Emerging hormonal agents for the treatment of prostate cancer
Expert Opin Emerg Drugs. 2022 Sep 5. doi: 10.1080/14728214.2022.2121390. Online ahead of print.ABSTRACTINTRODUCTION: Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal alternatives. The landscape of prostate cancer treatment has transformed and taken shape over the last 20 years with novel hormonal and non-hormonal therapeutics that have demonstrated significant improvement in survival. However, patients with advanced disease still face imminent progression on horm...
Source: Expert Opinion on Emerging Drugs - September 5, 2022 Category: Drugs & Pharmacology Authors: Emily Bochner Sam Gold Ganesh V Raj Source Type: research

Radiation Therapy in Oligometastatic Prostate Cancer
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging...
Source: International Journal of Radiation Oncology * Biology * Physics - July 22, 2022 Category: Radiology Authors: Siven Chinniah, Bradley Stish, Brian A. Costello, Lance Pagliaro, Daniel Childs, Fernando Quevedo, Fabrice Lucien, Alan Bryce, Sean S. Park, Jacob J. Orme Tags: CRITICAL REVIEW Source Type: research